Eli Lilly Wins Halt to Drug Discount Dispute Resolution Rule (1)

March 17, 2021, 2:23 PMUpdated: March 17, 2021, 7:28 PM

Eli Lilly & Co. has stopped the U.S. government from requiring drugmakers to administratively resolve disputes with medical providers over a federal drug discount program, convincing a federal court that the HHS didn’t comply with procedural standards when it adopted the dispute resolution rule.

The 340B Drug Pricing Program requires drugmakers participating in Medicare Part B and Medicaid to offer outpatient drugs to public and not-for-profit hospitals, community centers, and other federally funded clinics serving low-income patients at steeply discounted prices.

Eli Lilly is likely to prove the Department of Health and Human Services violated the Administrative Procedure Act by ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.